These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7542496)

  • 1. In vitro killing of neuroblastoma cells by neutrophils derived from granulocyte colony-stimulating factor-treated cancer patients using an anti-disialoganglioside/anti-Fc gamma RI bispecific antibody.
    Michon J; Moutel S; Barbet J; Romet-Lemonne JL; Deo YM; Fridman WH; Teillaud JL
    Blood; 1995 Aug; 86(3):1124-30. PubMed ID: 7542496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy.
    Valerius T; Repp R; de Wit TP; Berthold S; Platzer E; Kalden JR; Gramatzki M; van de Winkel JG
    Blood; 1993 Aug; 82(3):931-9. PubMed ID: 7687898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
    Repp R; Valerius T; Wieland G; Becker W; Steininger H; Deo Y; Helm G; Gramatzki M; Van de Winkel JG; Lang N
    J Hematother; 1995 Oct; 4(5):415-21. PubMed ID: 8581378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor.
    Repp R; Valerius T; Sendler A; Gramatzki M; Iro H; Kalden JR; Platzer E
    Blood; 1991 Aug; 78(4):885-9. PubMed ID: 1714327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo targeting of human neuroblastoma xenograft by anti-GD2/anti-Fc gamma RI (CD64) bispecific antibody.
    Michon J; Perdereau B; Brixy F; Moutel S; Fridman WH; Teillaud JL
    Eur J Cancer; 1995; 31A(4):631-6. PubMed ID: 7576984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
    Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
    Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysis of murine B lymphoma cells by transgenic phagocytes via a human Fc gamma RI x murine MHC class II bispecific antibody.
    Heijnen IA; Glennie MJ; van de Winkel JG
    Cancer Immunol Immunother; 1997; 45(3-4):166-70. PubMed ID: 9435865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.
    Valerius T; Stockmeyer B; van Spriel AB; Graziano RF; van den Herik-Oudijk IE; Repp R; Deo YM; Lund J; Kalden JR; Gramatzki M; van de Winkel JG
    Blood; 1997 Dec; 90(11):4485-92. PubMed ID: 9373259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).
    Ball ED; Guyre PM; Mills L; Fisher J; Dinces NB; Fanger MW
    J Hematother; 1992; 1(1):85-94. PubMed ID: 1365020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor.
    Elsässer D; Valerius T; Repp R; Weiner GJ; Deo Y; Kalden JR; van de Winkel JG; Stevenson GT; Glennie MJ; Gramatzki M
    Blood; 1996 May; 87(9):3803-12. PubMed ID: 8611706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the ability of red cells sensitized with a bispecific anti-D x anti-Fc gamma RIII Fab fragment to activate human K cells and peritoneal macrophages through Fc gamma RIII.
    Bakács T; Hadley AG; Kumpel BM; Segal DM; Banhidy F
    Immunol Lett; 1994 Sep; 42(1-2):91-5. PubMed ID: 7829136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fc gamma RI and Fc gamma RII on monocytes and granulocytes are cytotoxic trigger molecules for tumor cells.
    Graziano RF; Fanger MW
    J Immunol; 1987 Nov; 139(10):3536-41. PubMed ID: 2960735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fc gamma R-mediated killing by eosinophils.
    Graziano RF; Looney RJ; Shen L; Fanger MW
    J Immunol; 1989 Jan; 142(1):230-5. PubMed ID: 2521234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The functional properties of Fc gamma RI, II and III on myeloid cells: a comparative study of killing of erythrocytes and tumor cells mediated through the different Fc receptors.
    Shen L; Graziano RF; Fanger MW
    Mol Immunol; 1989 Oct; 26(10):959-69. PubMed ID: 2531842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies.
    Heijnen IA; Rijks LJ; Schiel A; Stockmeyer B; van Ojik HH; Dechant M; Valerius T; Keler T; Tutt AL; Glennie MJ; van Royen EA; Capel PJ; van de Winkel JG
    J Immunol; 1997 Dec; 159(11):5629-39. PubMed ID: 9548506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood.
    Deo YM; Sundarapandiyan K; Keler T; Wallace PK; Graziano RF
    J Immunol; 1998 Feb; 160(4):1677-86. PubMed ID: 9469424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functions of the various IgG Fc receptors in mediating killing of Toxoplasma gondii.
    Erbe DV; Pfefferkorn ER; Fanger MW
    J Immunol; 1991 May; 146(9):3145-51. PubMed ID: 1826707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.
    Martinez Sanz P; van Rees DJ; van Zogchel LMJ; Klein B; Bouti P; Olsman H; Schornagel K; Kok I; Sunak A; Leeuwenburg K; Timmerman I; Dierselhuis MP; Kholosy WM; Molenaar JJ; van Bruggen R; van den Berg TK; Kuijpers TW; Matlung HL; Tytgat GAM; Franke K
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the antibody-dependent cytotoxic capabilities of individual human monocytes. Role of Fc gamma RI and Fc gamma RII and the effects of cytokines at the single cell level.
    Connor RI; Shen L; Fanger MW
    J Immunol; 1990 Sep; 145(5):1483-9. PubMed ID: 1696598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma.
    Elsässer D; Stadick H; Stark S; Van de Winkel JG; Gramatzki M; Schrott KM; Valerius T; Schafhauser W
    Anticancer Res; 1999; 19(2C):1525-8. PubMed ID: 10365137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.